{"entity":{"type":"insider","cik":"0001456591","url":"/insider/0001456591","json_url":"/insider/0001456591.json","name":"Versant Side Fund IV, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":19,"n_filings":6,"first":"2011-11-17","last":"2024-08-12","span_basis":"filed_date"},"name_variants":[{"name":"Versant Side Fund IV, L.P.","source":"filing","n_filings":6,"first_seen":"2011-11-17","last_seen":"2024-08-12"}],"transactions":[{"id":2827819,"accession":"0000950170-24-095675","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-095675","line_url":"/filing/0000950170-24-095675#line-2","is_derivative":false,"issuer_cik":"0001456589","issuer_name":"Tempest Therapeutics, Inc.","issuer_ticker":"TPST","issuer_name_source":null,"issuer_url":"/issuer/0001456589","owner_cik":null,"owner_name":"Versant Side Fund IV, L.P.; Versant Vantage II GP, L.P.; Versant Vantage II GP-GP, LLC; Versant Vantage II, L.P.; Versant Venture Capital IV, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures IV, LLC; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Side Fund IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":387999.0,"shares_display":"387,999","price_per_share":1.1005,"price_display":"1.10","price_state":"stated","total_value":426992.8995,"total_display":"426,992.90","total_whole":"426,993","shares_owned_after":209941.0,"shares_owned_after_display":"209,941","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-12","filed_date":"2024-08-12","scope":"insider"},{"id":2827813,"accession":"0000950170-24-095675","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-095675","line_url":"/filing/0000950170-24-095675#line-1","is_derivative":false,"issuer_cik":"0001456589","issuer_name":"Tempest Therapeutics, Inc.","issuer_ticker":"TPST","issuer_name_source":null,"issuer_url":"/issuer/0001456589","owner_cik":null,"owner_name":"Versant Side Fund IV, L.P.; Versant Vantage II GP, L.P.; Versant Vantage II GP-GP, LLC; Versant Vantage II, L.P.; Versant Venture Capital IV, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures IV, LLC; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Side Fund IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400000.0,"shares_display":"400,000","price_per_share":1.3501,"price_display":"1.35","price_state":"stated","total_value":540040.0,"total_display":"540,040.00","total_whole":"540,040","shares_owned_after":597940.0,"shares_owned_after_display":"597,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-08","filed_date":"2024-08-12","scope":"insider"},{"id":5328599,"accession":"0000899243-21-040777","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-21-040777","line_url":"/filing/0000899243-21-040777","is_derivative":false,"issuer_cik":"0001456589","issuer_name":"Oyster Point Pharma, Inc.","issuer_ticker":"OYST","issuer_name_source":null,"issuer_url":"/issuer/0001456589","owner_cik":null,"owner_name":"Versant Vantage I GP-GP, LLC; Versant Side Fund IV, L.P.; Versant Ventures IV, LLC; Versant Vantage I, L.P.; Versant Vantage I GP, L.P.; Versant Ventures VI GP, L.P.; Versant Venture Capital IV, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP-GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":550000.0,"shares_display":"550,000","price_per_share":14.837702561454545,"price_display":"14.84","price_state":"stated","total_value":8160736.4088,"total_display":"8,160,736.41","total_whole":"8,160,736","shares_owned_after":1057976.0,"shares_owned_after_display":"1,057,976","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-10-18","filed_date":"2021-10-20","scope":"insider","n_lines":4},{"id":8144011,"accession":"0000899243-19-026602","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0000899243-19-026602","line_url":"/filing/0000899243-19-026602","is_derivative":false,"issuer_cik":"0001456589","issuer_name":"Oyster Point Pharma, Inc.","issuer_ticker":"OYST","issuer_name_source":null,"issuer_url":"/issuer/0001456589","owner_cik":null,"owner_name":"Versant Ventures IV, LLC; Versant Vantage I, L.P.; Versant Vantage I GP-GP, LLC; Versant Venture Capital VI, L.P.; Versant Ventures VI GP-GP, LLC; Versant Venture Capital IV, L.P.; Versant Ventures VI GP, L.P.; Versant Side Fund IV, L.P.; Versant Vantage I GP, L.P.","owner_display_name":"Versant Ventures IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":590000.0,"shares_display":"590,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":9440000.0,"total_display":"9,440,000.00","total_whole":"9,440,000","shares_owned_after":1003658.0,"shares_owned_after_display":"1,003,658","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-11-04","filed_date":"2019-11-04","scope":"insider","n_lines":3},{"id":6537463,"accession":"0000899243-18-010684","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0000899243-18-010684","line_url":"/filing/0000899243-18-010684","is_derivative":false,"issuer_cik":"0001456589","issuer_name":"CRISPR Therapeutics AG","issuer_ticker":"CRSP","issuer_name_source":null,"issuer_url":"/issuer/0001456589","owner_cik":null,"owner_name":"Versant Venture Capital V (Canada), LP; Versant Venture Capital IV, L.P.; Versant Ventures IV, LLC; Versant Ophthalmic Affiliates I, L.P.; Versant Side Fund IV, L.P.; Versant Affiliates Fund V, L.P.; Versant Venture Capital V, L.P.","owner_display_name":"Versant Venture Capital V (Canada), LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":101994.0,"shares_display":"101,994","price_per_share":50.6784844206522,"price_display":"50.68","price_state":"stated","total_value":5168901.34,"total_display":"5,168,901.34","total_whole":"5,168,901","shares_owned_after":1539576.0,"shares_owned_after_display":"1,539,576","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-04-23","filed_date":"2018-04-24","scope":"insider","n_lines":4},{"id":9223374,"accession":"0001104659-16-163806","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-16-163806","line_url":"/filing/0001104659-16-163806","is_derivative":false,"issuer_cik":"0001456590","issuer_name":"CRISPR Therapeutics AG","issuer_ticker":"CRSP","issuer_name_source":null,"issuer_url":"/issuer/0001456590","owner_cik":null,"owner_name":"Versant Affiliates Fund V, L.P.; Versant Ophthalmic Affiliates I, L.P.; Versant Side Fund IV, L.P.; Versant Venture Capital IV, L.P.; Versant Venture Capital V (Canada), LP; Versant Venture Capital V, L.P.","owner_display_name":"Versant Affiliates Fund V, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":161000.0,"shares_display":"161,000","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":2254000.0,"total_display":"2,254,000.00","total_whole":"2,254,000","shares_owned_after":4104045.0,"shares_owned_after_display":"4,104,045","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-10-24","filed_date":"2016-12-23","scope":"insider","n_lines":4},{"id":8879352,"accession":"0001104659-11-064948","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-11-064948","line_url":"/filing/0001104659-11-064948#line-2","is_derivative":false,"issuer_cik":"0001456589","issuer_name":"Clovis Oncology, Inc.","issuer_ticker":"CLVS","issuer_name_source":null,"issuer_url":"/issuer/0001456589","owner_cik":null,"owner_name":"Versant Ventures IV, LLC; Versant Side Fund IV, L.P.; Versant Venture Capital IV, L.P.","owner_display_name":"Versant Ventures IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":661323.0,"shares_display":"661,323","price_per_share":0.0,"price_display":null,"price_state":"not-stated","total_value":0.0,"total_display":null,"total_whole":null,"shares_owned_after":2159289.0,"shares_owned_after_display":"2,159,289","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-11-16","filed_date":"2011-11-17","scope":"insider"},{"id":8879349,"accession":"0001104659-11-064948","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-11-064948","line_url":"/filing/0001104659-11-064948#line-1","is_derivative":false,"issuer_cik":"0001456589","issuer_name":"Clovis Oncology, Inc.","issuer_ticker":"CLVS","issuer_name_source":null,"issuer_url":"/issuer/0001456589","owner_cik":null,"owner_name":"Versant Ventures IV, LLC; Versant Side Fund IV, L.P.; Versant Venture Capital IV, L.P.","owner_display_name":"Versant Ventures IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4165.0,"shares_display":"4,165","price_per_share":0.0,"price_display":null,"price_state":"not-stated","total_value":0.0,"total_display":null,"total_whole":null,"shares_owned_after":13600.0,"shares_owned_after_display":"13,600","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-11-16","filed_date":"2011-11-17","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001544227","name":"Tempest Therapeutics, Inc.","url":"/issuer/0001544227","role":"Ten percent owner","n_filings":1,"first_seen":"2024-08-12","last_seen":"2024-08-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001720725","name":"Oyster Point Pharma, Inc.","url":"/issuer/0001720725","role":"Ten percent owner","n_filings":2,"first_seen":"2019-11-04","last_seen":"2021-10-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001674416","name":"CRISPR Therapeutics AG","url":"/issuer/0001674416","role":"Ten percent owner","n_filings":2,"first_seen":"2016-12-23","last_seen":"2018-04-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001466301","name":"Clovis Oncology, Inc.","url":"/issuer/0001466301","role":"Ten percent owner","n_filings":1,"first_seen":"2011-11-17","last_seen":"2011-11-17"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001456591","retrieved_at":"2026-08-22T15:56:58+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}